Exousia Pro, now NexTel Medical, signs deal to buy JumpstartRx, NueVistraMed for $8 million

MARIJUANA INC

MAJI

0.00

Exousia Pro agreed to buy telehealth and clinical platforms JumpstartRx and NueVistraMed for USD 8 million.
Consideration includes USD 2 million cash, USD 6 million preferred stock, and a USD 1 million performance bonus tied to revenue targets.
Targets contribute about USD 135,000 in monthly recurring revenue before planned scaling initiatives.
Closing expected in 60 to 75 days, subject to delivery of audited financial statements for both businesses.
Deal adds a distribution network of more than 1,500 online clinics and 350 medical facilities to support Maxasome commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exousia Pro Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606021123PRIMZONEFULLFEED9730578) on June 02, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.